Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Myambutol

Myambutol is a medicine containing the active ingredient(s) ethambutol. On this page you will find out more about Myambutol, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: ethambutol

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Myambutol 100 mg film-coated tablet, 56

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

INDICATIONS AS AT 04 JAN 2002 : Oral Administation : MYAMBUTOL is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. It has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculois meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculous of the shin and tuberculous eye diseases. It should not be used as the sole antituberculosis drug, but should be used in conjuction with at least one other antituberculosis drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - MYAMBUTOL, isoniazid, rifampicin and streptomycin - for the first 2-4 months for example, MYAMBUTOL plus isoniazid plus rifampicin or MYAMBUTOL plus isoniazid plus streptomycin then continuing with a two drug regimen such as MYAMBUTOL plus isoniazid or MYAMBUTOL plus rifampicin. In patients who have received previous antituberculosis therapy, mycobacterial resistance to other durgs used in initial therapy is frequent. Consequently, in such retreatment cases MYAMBUTOL should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculosis drugs used with MYAMBUTOL have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been use in multiple drug regimens. Alternating drug regimens have also been utilised.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Yellow tablets, glossy, round, standard biconvex, 5/16" diameter.
Dosage Form Tablet, film coated
Route of administration Oral
Medicine schedule
56 tablets: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Bottle
Storage temperature Store below 25 degrees Celsius
Storage conditions Protect from Moisture
Life time 5 Years
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo